Antibiotic News and Research RSS Feed - Antibiotic News and Research

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Hospira acquires API manufacturing and R&D facilities from Orchid for about $218 million

Hospira acquires API manufacturing and R&D facilities from Orchid for about $218 million

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million. [More]
DFG to establish five new Research Units to pursue current issues in research areas

DFG to establish five new Research Units to pursue current issues in research areas

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing five new Research Units. [More]
Research roundup: 20M gain insurance, coverage's effect on surgery choices; opioid use by service members

Research roundup: 20M gain insurance, coverage's effect on surgery choices; opioid use by service members

This report aims to help readers understand recently announced enrollment numbers, as well as other numbers that have received less attention, and assess their importance for the future of the ACA and our health care system. . [More]
Antibiotic therapy: A potential game-changer for hemodialysis treatment

Antibiotic therapy: A potential game-changer for hemodialysis treatment

An antibiotic therapy known to reduce catheter-related bloodstream infections in hemodialysis patients has been shown for the first time to reduce mortality, according to a Henry Ford Health System study. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]
Bacteria can survive under antibiotic exposure by developing a biological timer

Bacteria can survive under antibiotic exposure by developing a biological timer

Hebrew University of Jerusalem researchers showed that when exposed to repeated cycles of antibiotics, bacteria evolved a new adaptation by remaining dormant for the treatment period. The results show for the first time that bacteria can develop a biological timer to survive under antibiotic exposure. [More]
Viewpoints: Abortion rights buffer; coming 'freakout' on health law; repercussions of malaria prevention

Viewpoints: Abortion rights buffer; coming 'freakout' on health law; repercussions of malaria prevention

A Unanimous Supreme Court: Abortion Rights Lose A Buffer
Yet on Thursday the Supreme Court, in McCullen v. Coakley, struck down that law for violating the First Amendment. [More]
New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states. [More]
Host-directed therapy: A new type of TB treatment

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy. [More]
Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex Disinfection Services, the world leader in UV room disinfection systems, testified yesterday before the U.S. House of Representatives Committee on Science, Space, and Technology; Subcommittee on Research and Technology; and Subcommittee on Oversight. [More]
First step toward new drugs that can transcend antibiotic resistance issues

First step toward new drugs that can transcend antibiotic resistance issues

Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health. [More]
Personalized antibiotic therapy can help fight antibiotic-resistant infections

Personalized antibiotic therapy can help fight antibiotic-resistant infections

The Centers for Disease Control and Prevention warned last fall that the U.S. faces "potentially catastrophic consequences" if it doesn't act quickly to combat the growing threat of antibiotic-resistant infections, which kill about 23,000 Americans a year. [More]

New rapid diagnostic test for multi-resistance to broad-spectrum antibiotics

A rapid diagnostic test for multi-resistance to broad-spectrum antibiotics has just been developed at the University of Fribourg. Prof Patrice Nordmann and Dr Laurent Poirel of the Medical and Molecular Microbiology Unit have been collaborating with Unit 914 of the National Institute of Health and Medical Research (INSERM) in Paris, of which Patrice Nordmann is also Director. [More]
Current sequencing protocols overlook DNA crucial to bacterial virulence

Current sequencing protocols overlook DNA crucial to bacterial virulence

Genomic sequencing is supposed to reveal the entire genetic makeup of an organism. For infectious disease specialists, the technology can be used to analyze a disease-causing bacterium to determine how much harm it is capable of causing and whether or not it will be resistant to antibiotics. [More]
New article investigates effects of triclosan on health and environment

New article investigates effects of triclosan on health and environment

Earlier this year, mounting concerns over the potential health effects of triclosan, a common antimicrobial ingredient, prompted Minnesota to ban the germ-killer from consumer soaps statewide starting in 2017. [More]
Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine! [More]
Bruker receives CFDA clearance to market IVD MALDI Biotyper System in China

Bruker receives CFDA clearance to market IVD MALDI Biotyper System in China

Bruker Corporation today announced that it has received clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens. [More]
Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists at the University at Buffalo are turning to an old class of antibiotics to fight new superbugs resistant to modern medicine. [More]
Education campaign fails to improve guideline adherence in paediatric AOM

Education campaign fails to improve guideline adherence in paediatric AOM

Swedish researchers report that overall adherence to treatment guidelines for acute otitis media in children is good, at 70–90%, but that adherence to watchful waiting is poor. [More]
Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). [More]